New York, June 18, 2026, 11:57 (EDT)
- Pfizer fell about 3.2% to $25.09 in late-morning trade after saying CFO Dave Denton will leave on Aug. 15; Cecile Guegan will become interim CFO a day later.
- The change lands during Pfizer’s post-COVID reset, with investors focused on 2026 guidance, deal payoffs and its planned move into obesity drugs.
- U.S. stock trading was in a regular session Thursday, ahead of the NYSE’s Friday closure for Juneteenth.
Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild.
The shares were down 83 cents, or about 3.2%, at $25.09 around 11:42 a.m. EDT. That compared with a roughly 0.6% rise in the SPDR S&P 500 ETF Trust, a widely used tracker of the S&P 500 index.
This matters now because Denton has been one of the senior executives tied to Pfizer’s attempt to move past the boom-and-bust cycle of COVID vaccine and antiviral sales. Reuters reported that his tenure included the Seagen, Biohaven and Metsera deals, all meant to cushion falling COVID revenue and coming patent losses.
Pfizer named Cecile Guegan, senior vice president of finance for its global biopharmaceuticals business, as interim CFO from Aug. 16 while it runs an internal and external search. Chief Executive Albert Bourla said Guegan brings “deep institutional knowledge and financial acumen,” while Denton said Pfizer is “in excellent hands.” Pfizer
The stock reaction was not just about a personnel move. It was about timing. Scotiabank analyst Louise Chen said Denton’s exit raises investor concerns about Pfizer’s 2026 forecast, succession plans and the move coming as the company prepares to enter the obesity market, Reuters reported.
Pfizer reaffirmed in May that it expected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings per share of $2.80 to $3.00. Adjusted earnings per share means profit per share after excluding certain items. The company also said first-quarter revenue from launched and acquired products grew 22% on an operational basis, meaning excluding currency swings.
Obesity is the high-stakes piece of the story. GLP-1 drugs, a class of medicines that mimic a gut hormone tied to appetite and blood sugar, have been dominated by Eli Lilly and Novo Nordisk. Pfizer hopes berobenatide, acquired through Metsera, can stand out as a monthly shot rather than a weekly one; Jim List, Pfizer’s chief internal medicine officer, told Reuters its long half-life gives it a “very smooth profile compared to weeklies.” Reuters
Pfizer’s own June data release said berobenatide showed almost 16% non-placebo-adjusted weight loss in one Phase 2b extension and that the company plans 10 Phase 3 studies in 2026. John B. Buse, a University of North Carolina professor, said the drug could be “practical and sustainable in real life” if approved. Pfizer
Peers did not give much cover. Johnson & Johnson fell about 2.5%, and Lilly lost about 1.5%, but Pfizer’s drop was steeper than both and sharper than the broader market move, pointing to a company-specific read-through from the CFO news.
The risk for bears is that the handoff proves orderly and the next CFO keeps the same capital discipline, making Thursday’s selloff look overdone. The downside case is less forgiving: a drawn-out search, weaker late-stage obesity data, or fresh questions about how Pfizer funds dividends, debt reduction and product launches could keep pressure on a stock still carrying the burden of the post-pandemic reset.
